Nature 443, 870-874 (19 October 2006) | doi:10.1038/nature05143; Received 14 March 2006; Accepted 7 August 2006; Published online 11 October 2006

Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism

Yuequan Shen1, Andrzej Joachimiak2, Marsha Rich Rosner1 & Wei-Jen Tang1

  1. Ben-May Institute for Cancer Research, The University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, USA
  2. Midwest Center for Structural Genomics and Structural Biology Center, Biosciences Division, Argonne National Laboratory, 9700 South Cass Avenue, Argonne, Illinois 60439, USA

Correspondence to: Wei-Jen Tang1 Correspondence and requests for materials should be addressed to W.T. (Email: wtang@uchicago.edu). Coordinates of the X-ray structures of the substrate-bound IDE have been deposited in the RCSB Protein Data Bank under accession code 2G54 (Zn2+-IDE–insulin-B-chain), 2G56 (Zn2+-free IDE–insulin-B-chain), 2G47 (IDE–As zlig(1–40)), 2G48 (IDE–amylin) and 2G49 (IDE–glucagon).

Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-beta (refs 1–3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-beta, whereas enhanced IDE activity effectively reduces brain amyloid-beta (refs 4–7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-beta peptide (1–40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form beta-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-beta and blood sugar concentrations1, 8, 9.


These links to content published by NPG are automatically generated.


Production of an antigenic peptide by insulin-degrading enzyme

Nature Immunology Article (01 May 2010)

Extra navigation